IP Library › Granted Patent US 12,297,253
Granted Patent B2
US 12,297,253 · App. 16/959,662 · Granted May 13, 2025

Multi-domain immunomodulatory proteins and methods of use thereof

Inventor: Ryan Swanson (Seattle, WA)
Assignee: Alpine Immune Sciences, Inc.
C07K14/70532C07K16/2896C07K16/461C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,297,253
App. No.
16/959,662
Granted
May 13, 2025
Kind
B2
Abstract

Provided herein are multi-domain immunomodulatory proteins, nucleic acids encoding such immunomodulatory proteins, cells engineered to express the immunomodulatory proteins and infectious agents containing nucleic acid encoding the immunomodulatory proteins. The immunomodulatory proteins bind both an inhibitory receptor and a receptor involved in activation signaling cascades in an immune cell, such as a T cell. The immunomodulatory proteins, engineered cells and infectious agents provide therapeutic utility for a variety of immunological diseases or conditions. Compositions and methods for making and using such proteins are provided.

Claims (46)

1. An immunomodulatory polypeptide comprising,

an activating receptor binding molecule (ARBM), wherein the ARBM comprises a variant CTLA-4 polypeptide comprising an L63P amino acid modification, wherein the variant CTLA-4 polypeptide amino acids are numbered with reference to SEQ ID NO: 36; and

an inhibitory receptor binding molecule (IRBM), wherein the IRBM comprises a variant PD-L1 polypeptide comprising an N45D amino acid modification, wherein the variant PD-L1 polypeptide amino acids are numbered with reference to SEQ ID NO: 309.

2. The polypeptide of claim 1 comprising (i) the ARBM, (ii) a first peptide linker, (iii) an immunoglobulin Fc region, (iv) a second peptide linker, and (v) the IRBM.

3. The polypeptide of claim 1 , wherein the variant PD-L1 polypeptide further comprises one or more amino acid modifications selected from the group consisting of I20L, K28E, D43G, L56Q, V58A, N78I, Q89R, and G101G-ins.

4. The polypeptide of claim 3 , wherein the variant PD-L1 polypeptide comprises the amino acid modifications D43G/N45D/L56Q/V58A/G101G-ins, I20L/D43G/N45D/N78I, or I20L/K28E/D43G/N45D/V58A/Q89R/G101G-ins.

5. The polypeptide of claim 3 , wherein the variant PD-L1 polypeptide comprises the sequence of SEQ ID NO: 303, 292, or 1727.

6. The polypeptide of claim 1 , wherein the variant CTLA-4 polypeptide further comprises one or more amino acid modifications selected from the group consisting of G29W, T53S, M56K, N58S, Q82R, M87V, L98Q, and Y105L.

7. The polypeptide of claim 6 , wherein the variant CTLA-4 polypeptide comprises the amino acid modifications G29W/N58S/L63P/Q82R/L98Q/Y105L, T53S/L63P/Y105L, or M56K/N58S/L63P/M87V/L98Q/Y105L.

8. The polypeptide of claim 6 , wherein the variant CTLA-4 polypeptide comprises the sequence of SEQ ID NO: 3037, 3591, or 3598.

9. The polypeptide of claim 1 , wherein the variant CTLA-4 polypeptide comprises the amino acid modifications G29W/N58S/L63P/Q82R/L98Q/Y105L and the variant PD-L1 polypeptide comprises the amino acid modifications D43G/N45D/L56Q/V58A/G101G-ins.

10. The polypeptide of claim 1 , wherein the variant CTLA-4 polypeptide comprises the amino acid modifications G29W/N58S/L63P/Q82R/L98Q/Y105L and the variant PD-L1 polypeptide comprises the amino acid modifications I20L/D43G/N45D/N781.

11. The polypeptide of claim 1 , wherein the variant CTLA-4 polypeptide comprises the amino acid modifications G29W/N58S/L63P/Q82R/L98Q/Y105L and the variant PD-L1 polypeptide comprises the amino acid modifications I20L/K28E/D43G/N45D/V58A/Q89R/G101G-ins.

12. The polypeptide of claim 1 , wherein the variant CTLA-4 polypeptide comprises the sequence of SEQ ID NO: 3037 and the variant PD-L1 polypeptide comprises the sequence of SEQ ID NO: 303.

13. The polypeptide of claim 1 , wherein the variant CTLA-4 polypeptide comprises the sequence of SEQ ID NO: 3037 and the variant PD-L1 polypeptide comprises the sequence of SEQ ID NO: 292.

14. The polypeptide of claim 1 , wherein the variant CTLA-4 polypeptide comprises the sequence of SEQ ID NO: 3037 and the variant PD-L1 polypeptide comprises the sequence of SEQ ID NO: 1727.

15. The polypeptide of claim 2 , wherein each of the first peptide linker and the second peptide linker is selected from:

(i) [G x S y ] z , where x is an integer from 1 to 4, y is 0 or 1, and z is an integer from 1 to 50,

(ii) S(G 4 S) n , where n is an integer from 1 to 20,

(iii) (GA) n , where n is an integer from 1 to 20,

(iv) (A) n , where n is an integer from 1 to 20,

(v) (EAAAK) n , where n is an integer from 1 to 20,

(vi) GGGGS (SEQ ID NO: 1942), GGGGSGGGGS (2×GGGGS; SEQ ID NO: 240), GGGGSGGGGSGGGGS (3×GGGGS; SEQ ID NO: 239), 4×GGGGS, 5×GGGGS, GSGGS (SEQ ID NO: 2523), GSGGGGS (SEQ ID NO: 1941), GGGGSSA (SEQ ID NO: 2524), GGGGSGGGGSAAA (SEQ ID NO:241), EAAAK (SEQ ID NO: 3240), 3×EAAAK (SEQ ID NO: 3241), 5×EAAAK (SEQ ID NO: 3242), and

(vii) combinations thereof.

16. The polypeptide of claim 2 , wherein the Fc region is at least 85% identical to SEQ ID NO: 187.

17. The polypeptide of claim 16 , wherein the Fc region comprises one or more modifications selected from the group consisting of C5S, L19A, L20E, G22A, E141D, M143L, and deletion of K232, wherein the Fc region amino acids are numbered with reference to SEQ ID NO: 187.

18. The polypeptide of claim 17 , wherein the Fc region comprises the modifications C5S, L19A, L20E, G22A, E141D, M143L and deletion of K232.

19. The polypeptide of claim 18 , wherein the Fc region comprises the sequence of SEQ ID NO: 1715.

20. The polypeptide of claim 2 , wherein the N-terminal to C-terminal orientation is: the variant CTLA-4 polypeptide, the first peptide linker, the Fc region, the second peptide linker, and the variant PD-L1 polypeptide.

21. The polypeptide of claim 20 , wherein the variant CTLA-4 polypeptide comprises the sequence of SEQ ID NO: 3037, the first peptide linker comprises the sequence of SEQ ID NO: 1941, the Fc region comprises the sequence of SEQ ID NO: 1715, the second peptide linker comprises the sequence of SEQ ID NO: 239, and the variant PD-L1 polypeptide comprises the sequence of SEQ ID NO: 303.

22. The polypeptide of claim 20 , wherein the variant CTLA-4 polypeptide comprises the sequence of SEQ ID NO: 3037, the first peptide linker comprises the sequence of SEQ ID NO: 1941, the Fc region comprises the sequence of SEQ ID NO: 1715, the second peptide linker comprises the sequence of SEQ ID NO: 239, and the variant PD-L1 polypeptide comprises the sequence of SEQ ID NO: 292.

23. The polypeptide of claim 20 , wherein the variant CTLA-4 polypeptide comprises the sequence of SEQ ID NO: 3037, the first peptide linker comprises the sequence of SEQ ID NO: 1941, the Fc region comprises the sequence of SEQ ID NO: 1715, the second peptide linker comprises the sequence of SEQ ID NO: 239, and the variant PD-L1 polypeptide comprises the sequence of SEQ ID NO: 1727.

24. The polypeptide of claim 2 , wherein the N-terminal to C-terminal orientation is: the Fc region, the first peptide linker, the variant CTLA-4 polypeptide, the second peptide linker, and the variant PD-L1 polypeptide.

25. The polypeptide of claim 24 , wherein the Fc region comprises the sequence of SEQ ID NO: 1715, the first peptide linker comprises the sequence of SEQ ID NO: 239, the variant CTLA-4 polypeptide comprises the sequence of SEQ ID NO: 3037, the second peptide linker comprises the sequence of SEQ ID NO: 239, and the variant PD-L1 polypeptide comprises the sequence of SEQ ID NO: 303, 292, or 1727.

26. A nucleic acid molecule encoding the polypeptide of claim 1 .

27. A vector, comprising the nucleic acid molecule of claim 26 .

28. The vector of claim 27 , wherein the vector is an expression vector.

29. A cell, comprising the nucleic acid of claim 26 .

30. A method of producing a polypeptide, comprising introducing the nucleic acid molecule of claim 26 into a host cell under conditions to express the protein in the cell.

31. The method of claim 30 , further comprising isolating or purifying the polypeptide from the cell.

32. A pharmaceutical composition, comprising the polypeptide of claim 1 and a pharmaceutically acceptable excipient.

33. An article of manufacture comprising the pharmaceutical composition of claim 32 in a vial or container.

34. A kit comprising the pharmaceutical composition of claim 32 or the article of manufacture of claim 33 , and instructions for use.

35. A method of decreasing an immune response in a subject, comprising administering the pharmaceutical composition of claim 32 to the subject.

36. The method of claim 35 , wherein decreasing the immune response treats Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis, a vasculitis, an autoimmune skin disease, transplantation, a Rheumatic disease, a thyroiditis, an inflammatory gastrointestinal disease, an inflammatory eye disease, an inflammatory neurological disease, an inflammatory pulmonary disease, an inflammatory endocrine disease, an autoimmune hematological disease, an autoimmune demyelinating disease, an autoimmune disease involving a systemic autoimmune disorder, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, asthma, autoimmune asthma, lupus erythematosus, celiac disease, Guillain-Barre syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, Graves' disease, DeQuervains thyroiditis, Vasculitis, autoimmune atrophic gastritis of pernicious anemia, autoimmune encephalomyelitis, autoimmune thrombocytopenia, sympathetic opthalmia, chronic aggressive hepatitis, membranous glomerulopathy, primary idiopathic myxedema, chronic hepatitis, hypogonadism, pernicious anemia, autoimmune enteropathy syndrome, acquired splenic atrophy, idiopathic diabetes insipidus, infertility due to antispermatazoan antibodies, sensoneural hearing loss, transverse myelitis, ataxic sclerosis, Pemphigus , progressive systemic sclerosis, polyarteritis nodosa, hemolytic anemia, glomerular nephritis, and idiopathic facial paralysis, giant cell arteritis (GCA), cancer, Addison's Disease, Allergy, Alopecia Areata, Alzheimer's, Ankylosing Spondylitis, Antiphospholipid Syndrome (Hughes Syndrome), Arthritis, Atherosclerosis, Atherosclerotic plaque, autoimmune disease, Autoimmune Hemolytic Anemia, Autoimmune Hepatitis, Autoimmune inner ear disease, Autoimmune Lymphoproliferative syndrome, Autoimmune Myocarditis, Autoimmune Oophoritis, Autoimmune Orchitis, Azoospermia, Behcet's Disease, Berger's Disease, Bullous Pemphigoid, Cardiomyopathy, Cardiovascular disease, Celiac Sprue/Coeliac disease, Chronic Fatigue Immune Dysfunction Syndrome (CFIDS), Chronic idiopathic polyneuritis, Chronic Inflammatory Demyelinating Polyradicalneuropathy (CIPD), Chronic relapsing polyneuropathy (Guillain-Barre syndrome), Churg-Strauss Syndrome (CSS), Cicatricial Pemphigoid, Cold Agglutinin Disease (CAD), COPD, CREST syndrome, Dermatitis, Herpetiformus, Dermatomyositis, diabetes, Discoid Lupus, Eczema, Epidermolysis bullosa acquisita, Essential Mixed Cryoglobulinemia, Evan's Syndrome, Exopthalmos, Fibromyalgia, Goodpasture's Syndrome, graft-related disease or disorder, GVHD, Hashimoto's Thyroiditis, Idiopathic Pulmonary Fibrosis, Idiopathic Thrombocytopenia Purpura (ITP), IgA Nephropathy, immunoproliferative disease or disorder, Insulin Dependent Diabetes Mellitus (IDDM), Interstitial lung disease, juvenile diabetes, Juvenile Arthritis, juvenile idiopathic arthritis (JIA), Kawasaki's Disease, Lambert-Eaton Myasthenic Syndrome, Lichen Planus, Lupus, Lupus Nephritis, Lymphoscytic Lypophisitis, Ménière's Disease, Miller Fish Syndrome/acute disseminated encephalomyeloradiculopathy, Mixed Connective Tissue Disease, Multiple Sclerosis (MS), muscular rheumatism, Myalgic encephalomyelitis (ME), Myasthenia Gravis, Ocular Inflammation, Pemphigus Foliaceus, Pemphigus Vulgaris , Pernicious Anaemia, Polychondritis, Polyglandular Syndromes (Whitaker's syndrome), Polymyalgia Rheumatica, Polymyositis, Primary Agammaglobulinemia, Primary Biliary Cirrhosis/Autoimmune cholangiopathy, Psoriasis, Psoriatic arthritis, Raynaud's Phenomenon, Reiter's Syndrome/Reactive arthritis, Restenosis, Rheumatic Fever, rheumatic disease, Rheumatoid Arthritis, Sarcoidosis, Schmidt's syndrome, Scleroderma, Sjörgen's Syndrome, Solid-organ transplant rejection, Stiff-Man Syndrome, Systemic Lupus Erythematosus (SLE), systemic scleroderma, Takayasu Arteritis, Temporal Arteritis/Giant Cell Arteritis, Thyroiditis, Type 1 diabetes, Type 2 diabetes, Uveitis, Vitiligo, Wegener's Granulomatosis, an immune response associated with rejection of a donor tissue, cell, graft, or organ transplant by a recipient subject, graft versus host disease (GVDH), or interstitial bowel disease.

37. The method of claim 35 , wherein decreasing the immune response treats an inflammatory or autoimmune disease or condition.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 8, 2020
From: SWANSON, RYAN
To: ALPINE IMMUNE SCIENCES, INC.
Reel/Frame 054582/0310 →
Continuity (3)
Provisional Application 62733622 · Sep 19, 2018
Provisional Application 62613378 · Jan 3, 2018
Related Publication 20230101432A1 · Mar 30, 2023
References Cited (400)
US 4751180A · Cousens · 1988 [cited by applicant]
US 4935233A · Bell et al. · 1990 [cited by applicant]
US 5168062A · Stinski · 1992 [cited by applicant]
US 5208020A · Chari et al. · 1993 [cited by applicant]
US 5283173A · Fields et al. · 1994 [cited by applicant]
US 5385839A · Stinski · 1995 [cited by applicant]
US 5434131A · Linsley et al. · 1995 [cited by applicant]
US 5443964A · Pickup et al. · 1995 [cited by applicant]
US 5457035A · Baum et al. · 1995 [cited by applicant]
US 5468614A · Fields et al. · 1995 [cited by applicant]
US 5500362A · Robinson et al. · 1996 [cited by applicant]
US 5624821A · Winter et al. · 1997 [cited by applicant]
US 5641870A · Rinderknecht et al. · 1997 [cited by applicant]
US 5648260A · Winter et al. · 1997 [cited by applicant]
US 5698530A · Schlom et al. · 1997 [cited by applicant]
US 5716613A · Guber et al. · 1998 [cited by applicant]
US 5731168A · Carter et al. · 1998 [cited by applicant]
US 5767071A · Palladino et al. · 1998 [cited by applicant]
US 5773253A · Linsley et al. · 1998 [cited by applicant]
US 5780426A · Palladino et al. · 1998 [cited by applicant]
US 5821337A · Carter et al. · 1998 [cited by applicant]
US 5844095A · Linsley et al. · 1998 [cited by applicant]
US 5851529A · Guber et al. · 1998 [cited by applicant]
US 5851795A · Linsley et al. · 1998 [cited by applicant]
US 5885579A · Linsley et al. · 1999 [cited by applicant]
US 5885796A · Linsley et al. · 1999 [cited by applicant]
US 5891432A · Hoo · 1999 [cited by applicant]
US 5998205A · Hallenbeck et al. · 1999 [cited by applicant]
US 6143290A · Zhang et al. · 2000 [cited by applicant]
US 6194551B1 · Idusogie et al. · 2001 [cited by applicant]
US 6365619B1 · Shi · 2002 [cited by applicant]
US 6428968B1 · Molnar-Kimber et al. · 2002 [cited by applicant]
US 6444792B1 · Gray et al. · 2002 [cited by applicant]
US 6482919B2 · Ledbetter et al. · 2002 [cited by applicant]
US 6596535B1 · Carter · 2003 [cited by applicant]
US 6623940B1 · Ledbetter et al. · 2003 [cited by applicant]
US 6632670B1 · Wadsworth et al. · 2003 [cited by applicant]
US 6635472B1 · Lauermann · 2003 [cited by applicant]
US 6653103B2 · Petersen et al. · 2003 [cited by applicant]
US 6685941B1 · Thompson et al. · 2004 [cited by applicant]
US 6689871B1 · Wolfe et al. · 2004 [cited by applicant]
US 6723316B2 · Laquerre et al. · 2004 [cited by applicant]
US 6737056B1 · Presta · 2004 [cited by applicant]
US 6750334B1 · Gray et al. · 2004 [cited by applicant]
US 6855317B2 · Koelle et al. · 2005 [cited by applicant]
US 6887471B1 · Linsley et al. · 2005 [cited by applicant]
US 6897045B2 · Engelhardt et al. · 2005 [cited by applicant]
US 6936257B1 · Bennett · 2005 [cited by applicant]
US 6998252B1 · Moss et al. · 2006 [cited by applicant]
US 7001765B2 · Maass et al. · 2006 [cited by applicant]
US 7033826B2 · Perricaudet et al. · 2006 [cited by applicant]
US 7094874B2 · Peach et al. · 2006 [cited by applicant]
US 7094875B2 · Punnonen et al. · 2006 [cited by applicant]
US 7105166B1 · Linsley et al. · 2006 [cited by applicant]
US 7125717B2 · Carter · 2006 [cited by applicant]
US 7153510B1 · Rose · 2006 [cited by applicant]
US 7172893B2 · Rabinowitz et al. · 2007 [cited by applicant]
US 7238526B2 · Wilson et al. · 2007 [cited by applicant]
US 7241447B1 · Engelhardt et al. · 2007 [cited by applicant]
US 7247615B2 · Schlom et al. · 2007 [cited by applicant]
US 7304033B2 · Larsen et al. · 2007 [cited by applicant]
US 7307064B2 · Rusnak · 2007 [cited by applicant]
US 7332303B2 · Schilling et al. · 2008 [cited by applicant]
US 7332581B2 · Presta · 2008 [cited by applicant]
US 7368116B2 · Schlom et al. · 2008 [cited by applicant]
US 7371826B2 · Presta · 2008 [cited by applicant]
US 7378087B2 · Jefferies et al. · 2008 [cited by applicant]
US 7439230B2 · Peach et al. · 2008 [cited by applicant]
US 7455835B2 · Cohen et al. · 2008 [cited by applicant]
US 7482327B2 · Hagerty et al. · 2009 [cited by applicant]
US 7521532B2 · Dunussi-Joannopoulos et al. · 2009 [cited by applicant]
US 7537924B2 · Coffin · 2009 [cited by applicant]
US 7550296B2 · Hermiston et al. · 2009 [cited by applicant]
US 7563869B2 · Honjo et al. · 2009 [cited by applicant]
US 7569663B2 · Tykocinski et al. · 2009 [cited by applicant]
US 7588767B2 · Szalay et al. · 2009 [cited by applicant]
US 7588771B2 · Szalay et al. · 2009 [cited by applicant]
US 7655439B2 · Moore et al. · 2010 [cited by applicant]
US 7662398B2 · Szalay et al. · 2010 [cited by applicant]
US 7662627B2 · Johnson, Jr. · 2010 [cited by applicant]
US 7670602B2 · Chung et al. · 2010 [cited by applicant]
US 7671022B2 · Rusnak · 2010 [cited by applicant]
US 7700556B2 · Peach et al. · 2010 [cited by applicant]
US 7722868B2 · Freeman et al. · 2010 [cited by applicant]
US 7731952B2 · Mohr et al. · 2010 [cited by applicant]
US 7731974B2 · Bell et al. · 2010 [cited by applicant]
US 7754221B2 · Szalay et al. · 2010 [cited by applicant]
US 7794718B2 · Karrer et al. · 2010 [cited by applicant]
US 7811814B2 · Bohn et al. · 2010 [cited by applicant]
US 7829534B2 · Larsen et al. · 2010 [cited by applicant]
US 7897146B2 · Brown et al. · 2011 [cited by applicant]
US 7906111B2 · Wilson et al. · 2011 [cited by applicant]
US 7915222B2 · Vratsanos et al. · 2011 [cited by applicant]
US 7915395B2 · Ledbetter et al. · 2011 [cited by applicant]
US 7927585B2 · Snyder · 2011 [cited by applicant]
US 7943374B2 · Hildinger · 2011 [cited by applicant]
US 7968340B2 · Hallek et al. · 2011 [cited by applicant]
US 8007780B2 · Arbetman et al. · 2011 [cited by applicant]
US 8071095B2 · Karrer et al. · 2011 [cited by applicant]
US 8088736B2 · Franks et al. · 2012 [cited by applicant]
US 8148332B2 · Cohen et al. · 2012 [cited by applicant]
US 8227420B2 · Cohen et al. · 2012 [cited by applicant]
US 8268587B2 · Karrer et al. · 2012 [cited by applicant]
US 8283447B2 · Karrer et al. · 2012 [cited by applicant]
US 8318176B2 · Karrer et al. · 2012 [cited by applicant]
US 8329867B2 · Lazar et al. · 2012 [cited by applicant]
US 8435952B2 · Vratsanos et al. · 2013 [cited by applicant]
US 8445230B2 · Karrer et al. · 2013 [cited by applicant]
US 8445447B2 · Chen · 2013 [cited by applicant]
US 8491899B2 · Karrer et al. · 2013 [cited by applicant]
US 8496935B2 · Karrer et al. · 2013 [cited by applicant]
US 8497247B2 · Cohen et al. · 2013 [cited by applicant]
US 8609625B2 · Lan et al. · 2013 [cited by applicant]
US 8624010B1 · Yoshinaga · 2014 [cited by applicant]
US 8629119B2 · Olson et al. · 2014 [cited by applicant]
US 8642557B2 · Akamatsu et al. · 2014 [cited by applicant]
US 8703718B2 · Cohen et al. · 2014 [cited by applicant]
US 8709417B2 · Allison et al. · 2014 [cited by applicant]
US 8722632B2 · Cohen et al. · 2014 [cited by applicant]
US 8785398B2 · Peach et al. · 2014 [cited by applicant]
US 8883971B2 · Akamatsu et al. · 2014 [cited by applicant]
US 8911726B2 · Takahashi et al. · 2014 [cited by applicant]
US 8956619B2 · Ostrand-Rosenberg · 2015 [cited by applicant]
US 9012408B2 · Vratsanos et al. · 2015 [cited by applicant]
US 9103831B2 · O'Sullivan et al. · 2015 [cited by applicant]
US 9289480B2 · Lan et al. · 2016 [cited by applicant]
US 9296808B2 · Cohen et al. · 2016 [cited by applicant]
US 9327014B2 · Gurney et al. · 2016 [cited by applicant]
US 9375475B2 · Allison et al. · 2016 [cited by applicant]
US 9453227B2 · Diamond et al. · 2016 [cited by applicant]
US 9540426B2 · Jing et al. · 2017 [cited by applicant]
US 9587007B2 · Akamatsu et al. · 2017 [cited by applicant]
US 9709568B2 · Pierce et al. · 2017 [cited by applicant]
US 9758565B2 · Peach et al. · 2017 [cited by applicant]
US 9834604B2 · Zhu et al. · 2017 [cited by applicant]
US 9884902B2 · Minter et al. · 2018 [cited by applicant]
US 10487147B2 · Nastri et al. · 2019 [cited by applicant]
US 10882914B2 · Swanson et al. · 2021 [cited by applicant]
US 11078282B2 · Swanson · 2021 [cited by examiner]
US 11096988B2 · Swanson et al. · 2021 [cited by applicant]
US 11117948B2 · Swanson et al. · 2021 [cited by applicant]
US 11117949B2 · Swanson et al. · 2021 [cited by applicant]
US 11117950B2 · Swanson et al. · 2021 [cited by applicant]
US 11319359B2 · Swanson · 2022 [cited by examiner]
US 11753458B2 · Evans · 2023 [cited by examiner]
US 20020009454A1 · Boone et al. · 2002 [cited by applicant]
US 20020168714A1 · Barbas et al. · 2002 [cited by applicant]
US 20030083246A1 · Cohen et al. · 2003 [cited by applicant]
US 20030138881A1 · Punnonen et al. · 2003 [cited by applicant]
US 20030158102A1 · Chen et al. · 2003 [cited by applicant]
US 20030232323A1 · Freeman · 2003 [cited by examiner]
US 20040009604A1 · Zhang et al. · 2004 [cited by applicant]
US 20040063094A1 · Coffin et al. · 2004 [cited by applicant]
US 20040072283A1 · Seed et al. · 2004 [cited by applicant]
US 20040146488A1 · Hu et al. · 2004 [cited by applicant]
US 20050014934A1 · Hinton et al. · 2005 [cited by applicant]
US 20050220818A1 · Lorence · 2005 [cited by applicant]
US 20050260601A1 · Whitt et al. · 2005 [cited by applicant]
US 20060024298A1 · Lazar et al. · 2006 [cited by applicant]
US 20060039894A1 · Mohr et al. · 2006 [cited by applicant]
US 20070098743A1 · Bell et al. · 2007 [cited by applicant]
US 20070110720A1 · Brown et al. · 2007 [cited by applicant]
US 20070202572A1 · Szalay et al. · 2007 [cited by applicant]
US 20070212727A1 · Szalay et al. · 2007 [cited by applicant]
US 20090010889A1 · Brown et al. · 2009 [cited by applicant]
US 20090053244A1 · Chen et al. · 2009 [cited by applicant]
US 20090098529A1 · Chen et al. · 2009 [cited by applicant]
US 20090117034A1 · Chen et al. · 2009 [cited by applicant]
US 20090136917A1 · Szalay et al. · 2009 [cited by applicant]
US 20090155287A1 · Chen et al. · 2009 [cited by applicant]
US 20090162288A1 · Chen et al. · 2009 [cited by applicant]
US 20090215147A1 · Zhang et al. · 2009 [cited by applicant]
US 20090252749A1 · Leister et al. · 2009 [cited by applicant]
US 20090258031A1 · Karrer et al. · 2009 [cited by applicant]
US 20090274728A1 · Brown et al. · 2009 [cited by applicant]
US 20090285860A1 · Martuza et al. · 2009 [cited by applicant]
US 20100062016A1 · Szalay et al. · 2010 [cited by applicant]
US 20100092515A1 · Conner et al. · 2010 [cited by applicant]
US 20100113567A1 · Barber · 2010 [cited by applicant]
US 20100178276A1 · Sadelain et al. · 2010 [cited by applicant]
US 20100178684A1 · Woo et al. · 2010 [cited by applicant]
US 20100196325A1 · Szalay et al. · 2010 [cited by applicant]
US 20100233078A1 · Szalay et al. · 2010 [cited by applicant]
US 20100261660A1 · Punnonen et al. · 2010 [cited by applicant]
US 20110064650A1 · Szalay · 2011 [cited by applicant]
US 20110064763A1 · Allen et al. · 2011 [cited by applicant]
US 20110158948A1 · Brown et al. · 2011 [cited by applicant]
US 20110159023A1 · Langermann · 2011 [cited by applicant]
US 20110177032A1 · Martuza et al. · 2011 [cited by applicant]
US 20110195068A1 · Langermann et al. · 2011 [cited by applicant]
US 20110212530A1 · Baltimore et al. · 2011 [cited by applicant]
US 20110293705A1 · Irvine et al. · 2011 [cited by applicant]
US 20110305712A1 · Akamatsu · 2011 [cited by examiner]
US 20130149305A1 · Ostrand-Rosenberg · 2013 [cited by applicant]
US 20130287748A1 · June et al. · 2013 [cited by applicant]
US 20130319861A1 · Khandros et al. · 2013 [cited by applicant]
US 20140011370A1 · Camphausen · 2014 [cited by applicant]
US 20140050708A1 · Powell et al. · 2014 [cited by applicant]
US 20140056890A1 · Gurney et al. · 2014 [cited by applicant]
US 20140099309A1 · Powell, Jr. et al. · 2014 [cited by applicant]
US 20140154216A1 · Coffin · 2014 [cited by applicant]
US 20140186380A1 · Gurney · 2014 [cited by applicant]
US 20140186401A1 · Diamond et al. · 2014 [cited by applicant]
US 20140227237A1 · June et al. · 2014 [cited by applicant]
US 20140322129A1 · Leong et al. · 2014 [cited by applicant]
US 20140348832A1 · Zhu et al. · 2014 [cited by applicant]
US 20150104451A1 · Orban · 2015 [cited by applicant]
US 20150216970A1 · Grogan et al. · 2015 [cited by applicant]
US 20150232532A1 · Ostrand-Rosenberg · 2015 [cited by applicant]
US 20150359909A1 · O'Sullivan et al. · 2015 [cited by applicant]
US 20160017018A1 · Wang et al. · 2016 [cited by applicant]
US 20160017041A1 · Violette et al. · 2016 [cited by applicant]
US 20160145344A1 · Akbari · 2016 [cited by applicant]
US 20160158318A1 · Cohen et al. · 2016 [cited by applicant]
US 20160244524A1 · Allison et al. · 2016 [cited by applicant]
US 20160264643A1 · Lazar et al. · 2016 [cited by applicant]
US 20160271218A1 · Biro · 2016 [cited by applicant]
US 20160339066A1 · Szalay et al. · 2016 [cited by applicant]
US 20160340422A1 · Chen et al. · 2016 [cited by applicant]
US 20160346368A1 · Gurney et al. · 2016 [cited by applicant]
US 20160376346A1 · Camphausen · 2016 [cited by applicant]
US 20170028040A1 · Lan et al. · 2017 [cited by applicant]
US 20170042972A1 · Karyekar · 2017 [cited by applicant]
US 20170081387A1 · Cai et al. · 2017 [cited by applicant]
US 20170189476A1 · Sung et al. · 2017 [cited by applicant]
US 20170320959A1 · Swanson et al. · 2017 [cited by applicant]
US 20170369549A1 · Peach et al. · 2017 [cited by applicant]
US 20180118805A1 · Bernett et al. · 2018 [cited by applicant]
US 20180244749A1 · Swanson et al. · 2018 [cited by applicant]
US 20180256644A1 · Swanson et al. · 2018 [cited by applicant]
US 20180319861A1 · Lan · 2018 [cited by examiner]
US 20190135922A1 · Swanson et al. · 2019 [cited by applicant]
US 20190175654A1 · Swanson · 2019 [cited by examiner]
US 20200040059A1 · Swanson et al. · 2020 [cited by applicant]
US 20200283500A1 · Lawrence et al. · 2020 [cited by applicant]
US 20200308249A1 · Lawrence et al. · 2020 [cited by applicant]
US 20210130436A1 · Swanson et al. · 2021 [cited by applicant]
US 20210130437A1 · Swanson et al. · 2021 [cited by applicant]
US 20210155668A1 · Swanson et al. · 2021 [cited by applicant]
US 20210155669A1 · Swanson et al. · 2021 [cited by applicant]
US 20210163571A1 · Swanson et al. · 2021 [cited by applicant]
US 20210171603A1 · Swanson et al. · 2021 [cited by applicant]
US 20210188942A1 · Swanson et al. · 2021 [cited by applicant]
US 20210253668A1 · Swanson et al. · 2021 [cited by applicant]
US 20210347897A1 · Swanson et al. · 2021 [cited by applicant]
US 20210363219A1 · Swanson et al. · 2021 [cited by applicant]
US 20220242930A1 · Swanson · 2022 [cited by examiner]
US 20220372106A1 · Swanson et al. · 2022 [cited by applicant]
US 20230220039A1 · Swanson et al. · 2023 [cited by applicant]
US 20230250152A1 · Evans · 2023 [cited by examiner]
CN 1441810A · 2003 [cited by applicant]
CN 103987405A · 2014 [cited by applicant]
CN 105579471A · 2016 [cited by applicant]
EP 0757099 · 1997 [cited by applicant]
EP 1248802A2 · 2002 [cited by applicant]
EP 1385466A2 · 2004 [cited by applicant]
EP 1391213A1 · 2004 [cited by applicant]
EP 1520175A2 · 2005 [cited by applicant]
EP 1606411A1 · 2005 [cited by applicant]
EP 3020816A1 · 2016 [cited by applicant]
KR 20150135148 · 2015 [cited by applicant]
WO WO1993010151 · 1993 [cited by applicant]
WO WO1994011026 · 1994 [cited by applicant]
WO WO9411026A2 · 1994 [cited by applicant]
WO WO1994029351 · 1994 [cited by applicant]
WO WO1998050431 · 1998 [cited by applicant]
WO WO1999002711 · 1999 [cited by applicant]
WO WO1999038955 · 1999 [cited by applicant]
WO WO1999051642 · 1999 [cited by applicant]
WO WO2000042072 · 2000 [cited by applicant]
WO WO2001030843 · 2001 [cited by applicant]
WO WO2001092337 · 2001 [cited by applicant]
WO WO2002000717 · 2002 [cited by applicant]
WO WO2004029197 · 2004 [cited by applicant]
WO WO2004056312 · 2004 [cited by applicant]
WO WO2005063816 · 2005 [cited by applicant]
WO WO2005100402 · 2005 [cited by applicant]
WO WO2006019447 · 2006 [cited by applicant]
WO WO2006029879 · 2006 [cited by applicant]
WO WO2006073941A2 · 2006 [cited by applicant]
WO WO2007029879 · 2007 [cited by applicant]
WO WO2007052029 · 2007 [cited by applicant]
WO WO2008011636A2 · 2008 [cited by applicant]
WO WO2008047150 · 2008 [cited by applicant]
WO WO2008092117 · 2008 [cited by applicant]
WO WO2008155134 · 2008 [cited by applicant]
WO WO2009029342 · 2009 [cited by applicant]
WO WO2009076524 · 2009 [cited by applicant]
WO WO2009067800A1 · 2009 [cited by applicant]
WO WO2009126688 · 2009 [cited by applicant]
WO WO2010027827 · 2010 [cited by applicant]
WO WO2010027828A2 · 2010 [cited by applicant]
WO WO2011020024 · 2011 [cited by applicant]
WO WO2011056983A1 · 2011 [cited by applicant]
WO WO2011097477 · 2011 [cited by applicant]
WO WO2011103584A2 · 2011 [cited by applicant]
WO WO2011113019 · 2011 [cited by applicant]
WO WO2011109789A2 · 2011 [cited by applicant]
WO WO2011133886A2 · 2011 [cited by applicant]
WO WO2012079000 · 2012 [cited by applicant]
WO WO2012125850 · 2012 [cited by applicant]
WO WO2012141984 · 2012 [cited by applicant]
WO WO2012149364 · 2012 [cited by applicant]
WO WO2013003761 · 2013 [cited by applicant]
WO WO2013041029A1 · 2013 [cited by applicant]
WO WO2013130683 · 2013 [cited by applicant]
WO WO2013148049A1 · 2013 [cited by applicant]
WO WO2013149167A1 · 2013 [cited by applicant]
WO WO2013169338 · 2013 [cited by applicant]
WO WO2013184912 · 2013 [cited by applicant]
WO WO2014089169 · 2014 [cited by applicant]
WO WO2014138188A1 · 2014 [cited by applicant]
WO WO2014198002 · 2014 [cited by applicant]
WO WO2014207063 · 2014 [cited by applicant]
WO WO2015009856 · 2015 [cited by applicant]
WO WO2015107026 · 2015 [cited by applicant]
WO WO2015113494A1 · 2015 [cited by applicant]
WO WO2015120363A1 · 2015 [cited by applicant]
WO WO2016008976 · 2016 [cited by applicant]
WO WO2016011083 · 2016 [cited by applicant]
WO WO2016011264 · 2016 [cited by applicant]
WO WO2016022994 · 2016 [cited by applicant]
WO WO2016034678A2 · 2016 [cited by applicant]
WO WO2016073704 · 2016 [cited by applicant]
WO WO2016118577A1 · 2016 [cited by applicant]
WO WO2016164428 · 2016 [cited by applicant]
WO WO2016168771 · 2016 [cited by applicant]
WO WO2016154684A1 · 2016 [cited by applicant]
WO WO2016191643A2 · 2016 [cited by applicant]
WO WO2017023749 · 2017 [cited by applicant]
WO WO2017029389 · 2017 [cited by applicant]
WO WO2017019846A1 · 2017 [cited by applicant]
WO WO2017048878 · 2017 [cited by applicant]
WO WO2017055547 · 2017 [cited by applicant]
WO WO2017106061A1 · 2017 [cited by applicant]
WO WO2017181148 · 2017 [cited by applicant]
WO WO2017181152 · 2017 [cited by applicant]
WO WO2017201131 · 2017 [cited by applicant]
WO WO2018022945 · 2018 [cited by applicant]
WO WO2018022946 · 2018 [cited by applicant]
WO WO2018075978 · 2018 [cited by applicant]
WO WO2018170021 · 2018 [cited by applicant]
WO WO2018170026 · 2018 [cited by applicant]
WO WO2018170023A1 · 2018 [cited by applicant]
WO WO2019074983A1 · 2019 [cited by applicant]
WO WO2019136179 · 2019 [cited by applicant]
WO WO2020047329A1 · 2020 [cited by applicant]
WO WO2021226553A2 · 2021 [cited by applicant]
U.S. Appl. No. 18/355,539, filed Jul. 20, 2023, Evans; Lawrence. [cited by examiner]
Butte et al. (2008) Interaction of human PD-L1 and B7-1. Molecular Immunology, 45: 3567-3572. [cited by examiner]
Chaudhri et al. (2018) PD-L1 Binds to B7-1 Only in Cis on the Same Cell Surface. Cancer Immunol Res; 6(8); 921-929. [cited by examiner]
Australian Examination Report for Application No. 2018236224, dated Jan. 6, 2023, 5 pages. [cited by applicant]
Benson et al., “GenBank,” Nucleic Acids Res (2013) 41 (Database issue):D36-D42. [cited by applicant]
Biasini et al., “Swiss-Model: modelling protein tertiary and quaternary structure using evolutionary information,” Nucleic Acids Research, Jul. 2014, 42(W1), pp. W252-W258. [cited by applicant]
Brandt et al., “The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans,” Journal of Experimental Medicine, Jul. 2009, 206(7), pp. 1495-1503. [cited by applicant]
Burmeister et al., “ICOS controls the pool size of effector-memory and regulatory T cells,” The Journal of Immunology, Jan. 2008, 180(2), pp. 774-782. [cited by applicant]
Canadian Examination Report for Application No. 3053804, dated Dec. 28, 2022, 7 pages. [cited by applicant]
Chang et al., “The discovery of small molecule carbamates as potent dual alpha(4)beta(1)/alpha(4)beta(7) integrin antagonists,” Bioorganic & Medicinal Chemistry Letters, Jan. 2002, 12(2), pp. 159-163. [cited by applicant]
Chari et al., “Immunoconjugates containing novel maytansinoids: promising anticancer drugs,” Cancer Research, Jan. 1992, 52(1), pp. 127-131. [cited by applicant]
Condomines et al., “Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition,” PLoS One, Jun. 2015, 10(6):e0130518, pp. 1-15. [cited by applicant]
Corpet, “Multiple sequence alignment with hierarchical clustering,” Nucleic Acids Research, Nov. 1988, 16(22), pp. 10881-10890, (URL: multalin.toulouse.inra.fr/multalin/multalin.html.). [cited by applicant]
David et al., “Protein iodination with solid state lactoperoxidase,” Biochemistry, Feb. 1974, 13(5), pp. 1014-1021. [cited by applicant]
Dull et al., “A Third-Generation Lentivirus Vector with a Conditional Packaging System,” Journal of Virology, Nov. 1998, 72(11), pp. 8463-8471. [cited by applicant]
Duncan et al., “The binding site for C1 q on IgG,” Nature. Apr. 21, 1988;332(6166):738-740. [cited by applicant]
Esensten et al., “CD28 Costimulation: From Mechanism to Therapy,” Immunity, 2016, vol. 44(5), pp. 973-988. [cited by applicant]
European Search Report for Application No. 19704899.4 dated Jan. 11, 2022, 4 pages. [cited by applicant]
Evans et al., “Generation of Novellmmuno-Oncology Biologics via Directed Evolution of Variant IgSF Domains,” Poster Presentation for Immune Checkpoint Inhibitors, Boston, MA (Mar. 14-16, 2017) 1 page. [cited by applicant]
Evans et al., “Novel immunomodulatory proteins generated via directed evolution of variant IgSF domains,” Abstract for AAI Immunology 2017, Washington D.C. (May 12-16, 2017) 1 page Published April A852017. [cited by applicant]
Evans et al., “Novel immunomodulatory proteins generated via directed evolution of variant IgSF domains,” Poster for AAI Immunology 2017, Washington D.C. (May 12-16, 2017) 1 page. [cited by applicant]
Evans et al., “Therapeutic T Cell Activation Using Engineered Variant IgSF Domains,” Poster presented at Society for Immunotherapy of Cancer, National Harbor, MD, (Nov. 9-13, 2016) 1 page. [cited by applicant]
Ford et al., “Targeting co-stimulatory pathways: transplantation and autoimmunity,” Nat Rev Nephrol. (2014) 10(1):14-24. [cited by applicant]
Fraker et al., “Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril,” Biochem Biophys Res Commun. Feb. 28, 1978;80(4):849-857. [cited by applicant]
Garcia-Aragoncillo et al., “Design of virotherapy for effective tumor treatment,” Curr Opin Mol Ther. Aug. 2010;12(4):403-411. [cited by applicant]
Hallden et al., “Oncolytic virotherapy with modified adenoviruses and novel therapeutic targets,” Expert Opin Ther Targets. Oct. 2012;16(10):945-958. [cited by applicant]
Harris et al., “CD80 costimulation is essential for the induction of airway eosinophilia,” J Exp Med. Jan. 6, 1997;185(1):177-182. [cited by applicant]
Hinman L.M., et al., “Preparation and Characterization of Monoclonal Antibody Conjugates of the Calicheamicins: a Novel and Potent Family of Antitumor Antibiotics,” Cancer Research, 1993, vol. 53(14), pp. 3336-3342. [cited by applicant]
Hou et al., “A transendocytosis model of CTLA-4 function predicts its suppressive behavior on regulatory T cells,” J Immunol (2015) 94(5):2148-2159. [cited by applicant]
Hunter et al., “Preparation of iodine-131 labelled human growth hormone of high specific activity,” Nature. May 5, 1962; 194:495-496. [cited by applicant]
International Search Report for Application No. PCT/US2018/022265, mailed Aug. 8, 2018, 9 pages. [cited by applicant]
Kirn et al., “Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer,” Nat Rev Cancer. Jan. 2009;9(1):64-71. [cited by applicant]
Koenen et al., “A novel bispecific antihuman CD40/CD86 fusion protein with T-cell tolerizing potential,” Transplantation (2004) 78(10):1429-1438. [cited by applicant]
Lazetic et al., “Chimeric co-stimulatory molecules that selectively act through CD28 or CTLA-4 on human T cells,” J Biol Chem (2002)11 ;277(41):38660-38668. [cited by applicant]
Levin et al., “Novel Immunomodulatory Proteins Generated Via Directed Evolution of Variant IgSF Domains,” Abstract for Keystone Symposia: Immune Regulation in Autoimmunity and Cancer, Whistler, British page Available to… [cited by applicant]
Levin et al., “Novel Immunomodulatory Proteins Generated Via Directed Evolution of Variant IgSF Domains,” Poster presentation for Keystone Symposia: Immune Regulation in Autoimmunity and Cancer, Whistler, British Columb… [cited by applicant]
Lewis et al., “Novel immunomodulatory proteins generated via directed evolution of variant IgSF domains,” Abstract for Poster Presentation at the Federation of Clinical Immunology Societies Meeting, Chicago IL 72017(Jun… [cited by applicant]
Lewis et al., “Novel immunomodulatory proteins generated via directed evolution of variant IgSF domains,” Poster Presentation at the Federation of Clinical Immunology Societies Meeting, Chicago IL (Jun. 14, 2017), 1 pag… [cited by applicant]
Li et al., “Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6,” J Exp Med (2011) 208(4): 703-714. [cited by applicant]
Lin et al., “Specific and dual antagonists of alpha(4)beta(1) and alpha(4)beta(7) integrins,” Bioorg Med Chem Lett. Jan. 21, 2002 ;12(2):133-136. [cited by applicant]
Lin et al., “The PD-1/PD-L 1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors,” Proc Natl Acad Sci US A. (2008) 105(8):3011-3016. [cited by applicant]
Lode et al., “Targeted therapy with a novel enediyene antibiotic calicheamicin theta(I)1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma,” Cancer Res. (19… [cited by applicant]
Lundqvist et al., “31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one,” J Immunother Cancer, (2016) 4(Suppl 1):82, 53 pages. [cited by applicant]
Lundqvist et al., “31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two,” J Immunother Cancer, (2016) 4(Suppl 1):82, 53 pages. [cited by applicant]
Mandler et al., “Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines,” J Natl Cancer Inst. Oct. 4, 2000;92(19):1573-1581. [cited by applicant]
Mandler et al., “Modifications in synthesis strategy improve the yield and efficacy of geldanamycin-herceptin immunoconjugates,” Bioconjug Chem. Jul.-Aug 2002;13(4):786-791. [cited by applicant]
Mandler et al., “Synthesis and evaluation of antiproliferative activity of a geldanamycin-Herceptin immunoconjugate,” Bioorg Med Chem Lett. May 15, 2000;10(10):1025-1028. [cited by applicant]
Mauer et al., “ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, utilizes multiple mechanisms to elicit potent anti-tumor immunity superior to checkpoint blockade alone,” Journal for Immunotherapy… [cited by applicant]
McLoughlin et al., “TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and long-term follow-up,” Annals of Surgical Oncolo… [cited by applicant]
Mkaddem et al., “Understanding Fc Receptor Involvement in Inflammatory Diseases: From Mechanisms to New Therapeutic Tools,” Frontiers in Immunology, 10:811 (Year: 2019), 12 pages. [cited by applicant]
Narumi et al., “Adenovirus vector-mediated perforin expression driven by a glucocorticoid-inducible promoter inhibits tumor growth in vivo,” American Journal of Respiratory Cell and Molecular Biology, Dec. 1998, 19(6), … [cited by applicant]
Nygren, “Conjugation of horseradish peroxidase to Fab fragments with different homobifunctional and heterobifunctional cross-linking reagents. A comparative study,” The Journal of Histochemistry and Cytochemistry, May 1… [cited by applicant]